正电子发射断层扫描（PET）衍生的肿瘤指标可预测弥漫性大 B 细胞淋巴瘤的反应和无进展生存期。
PET-derived tumor metrics predict DLBCL response and progression-free survival.
机构信息
a Winship Cancer Institute , Emory University , Atlanta , GA , USA.
出版信息
Leuk Lymphoma. 2019 Aug;60(8):1965-1971. doi: 10.1080/10428194.2018.1562181. Epub 2019 Feb 4.
Abstract
[18F] fluorodeoxyglucose (FDG) - positron emission tomography (PET)/computed tomography (CT) is used to stage and assess response in diffuse large B-cell lymphoma (DLBCL), though the prognostic value of tumor metrics calculated from interim scans remains unsolved. We investigated the predictive value of interim and end-of-treatment (EOT) metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on progression-free survival (PFS) at 24 months in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Controlling for pretreatment MTV, a positive interim MTV was highly correlated with (0.86) and a significant predictor of a positive EOT MTV ( = .03). Interim MTV > 0 (HR 5.51, CI 1.13, 26.79) and EOT MTV > 4.68 (HR 10.75, CI 1.31, 105.48) were significant predictors of PFS24. Our data show PET-derived metrics of pretreatment and interim MTV offer significant predictive value for EOT response and PFS, and can guide future response-adapted treatment approaches for DLBCL patients that build on the R-CHOP backbone.
摘要
[18F]氟脱氧葡萄糖（FDG）-正电子发射断层扫描（PET）/计算机断层扫描（CT）用于弥漫性大 B 细胞淋巴瘤（DLBCL）的分期和反应评估，尽管从中间扫描计算的肿瘤指标的预后价值仍未解决。我们研究了在接受利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗的 DLBCL 患者中，中期和治疗结束（EOT）代谢肿瘤体积（MTV）和总病变糖酵解（TLG）对 24 个月无进展生存（PFS）的预测价值。在控制预处理 MTV 的情况下，中期 MTV 阳性与 EOT MTV 阳性高度相关（0.86），并且是 EOT MTV 阳性的显著预测因子（= 0.03）。中期 MTV > 0（HR 5.51，CI 1.13，26.79）和 EOT MTV > 4.68（HR 10.75，CI 1.31，105.48）是 PFS24 的显著预测因子。我们的数据表明，预处理和中期 MTV 的 PET 衍生指标对 EOT 反应和 PFS 具有显著的预测价值，并且可以为基于 R-CHOP 骨干的 DLBCL 患者的未来反应适应性治疗方法提供指导。
相似文献
1
PET-derived tumor metrics predict DLBCL response and progression-free survival.正电子发射断层扫描（PET）衍生的肿瘤指标可预测弥漫性大 B 细胞淋巴瘤的反应和无进展生存期。
Leuk Lymphoma. 2019 Aug;60(8):1965-1971. doi: 10.1080/10428194.2018.1562181. Epub 2019 Feb 4.
2
Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.基线18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的总病变糖酵解在弥漫性大B细胞淋巴瘤中的预后价值
Oncotarget. 2016 Dec 13;7(50):83544-83553. doi: 10.18632/oncotarget.13180.
3
Prognostic Value of F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen.风险适应性免疫化疗方案治疗弥漫性大 B 细胞淋巴瘤中 F-FDG PET/CT 的预后价值。
J Nucl Med. 2023 Apr;64(4):536-541. doi: 10.2967/jnumed.122.264740. Epub 2022 Dec 22.
4
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.预后模型整合基线和中期正电子发射计算机断层扫描在弥漫性大 B 细胞淋巴瘤患者的定量参数：从 SAKK38/07 临床试验事后分析。
Hematol Oncol. 2020 Dec;38(5):715-725. doi: 10.1002/hon.2805. Epub 2020 Oct 4.
5
Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma.PET/CT 代谢肿瘤体积对原发性胃肠道弥漫性大 B 细胞淋巴瘤的预后价值。
Cancer Sci. 2012 Mar;103(3):477-82. doi: 10.1111/j.1349-7006.2011.02164.x. Epub 2012 Jan 16.
6
F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.弥漫性大 B 细胞淋巴瘤的 F-FDG PET 播散特征可预测结局。
J Nucl Med. 2020 Jan;61(1):40-45. doi: 10.2967/jnumed.119.229450. Epub 2019 Jun 14.
7
Metabolic tumour area: a novel prognostic indicator based on F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.代谢肿瘤区：基于 F-FDG PET/CT 的新型预后指标，可用于 R-CHOP 时代弥漫性大 B 细胞淋巴瘤患者。
BMC Cancer. 2024 Jul 25;24(1):895. doi: 10.1186/s12885-024-12668-x.
8
[Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].[预处理（18）F-FDG PET-CT对晚期弥漫性大B细胞淋巴瘤患者的预后价值]
Zhonghua Zhong Liu Za Zhi. 2018 Jul 23;40(7):528-533. doi: 10.3760/cma.j.issn.0253-3766.2018.07.009.
9
Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.在弥漫性大B细胞淋巴瘤中，美国国立综合癌症网络国际预后指数相较于治疗前全身容积代谢性氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）指标的预后优势。
Eur J Haematol. 2015 Jun;94(6):532-9. doi: 10.1111/ejh.12467. Epub 2015 Mar 13.
10
High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.在利妥昔单抗时代，PET/CT中高总代谢肿瘤体积预示着弥漫性大B细胞淋巴瘤骨髓受累患者的预后更差。
Leuk Res. 2016 Mar;42:1-6. doi: 10.1016/j.leukres.2016.01.010. Epub 2016 Jan 24.
引用本文的文献
1
Prognostic value of a simple distance index derived from PET maximum intensity projection.基于PET最大强度投影得出的简单距离指数的预后价值。
Front Med (Lausanne). 2025 Jul 14;12:1565525. doi: 10.3389/fmed.2025.1565525. eCollection 2025.
2
Early assessment of therapeutic efficacy in lymphoma patients via a blood-based multi-omics response monitoring test.通过基于血液的多组学反应监测测试对淋巴瘤患者的治疗疗效进行早期评估。
BMC Cancer. 2025 Jul 1;25(1):1078. doi: 10.1186/s12885-025-14457-6.
3
Evaluating ΔMTV%, ΔD%, and %ΔSUV of F-FDG PET/CT for mid-treatment efficacy and prognosis in diffuse large B-cell lymphoma.评估¹⁸F-FDG PET/CT的ΔMTV%、ΔD%和%ΔSUV对弥漫性大B细胞淋巴瘤治疗中期疗效及预后的价值。
Discov Oncol. 2025 Mar 27;16(1):411. doi: 10.1007/s12672-025-02126-w.
4
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.作为预测弥漫性大B细胞淋巴瘤无进展生存期和总生存期的实用评分系统的组成部分，Ki67免疫组化表达水平≥70%、肿块较大（≥7.5 cm）、脑膜淋巴瘤病以及4个治疗周期后的中期PET ΔSUVmax<71% 。
Front Nucl Med. 2022 Apr 7;2:829138. doi: 10.3389/fnume.2022.829138. eCollection 2022.
5
Prognostic value of F-FDG PET/CT tumor metabolic parameters and Ki-67 in pre-treatment diffuse large B-cell lymphoma.F-FDG PET/CT肿瘤代谢参数及Ki-67在弥漫性大B细胞淋巴瘤治疗前的预后价值
Quant Imaging Med Surg. 2024 Jan 3;14(1):325-334. doi: 10.21037/qims-23-702. Epub 2023 Nov 30.
6
Prediction nomogram based on 18F-FDG PET/CT and clinical parameters for patients with diffuse large B-cell lymphoma.基于18F-FDG PET/CT和临床参数的弥漫性大B细胞淋巴瘤患者预测列线图
Ann Hematol. 2023 Nov;102(11):3115-3124. doi: 10.1007/s00277-023-05336-w. Epub 2023 Jul 3.
7
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.18F-氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描在淋巴瘤免疫治疗反应监测中的应用：现状与未来展望
Cancers (Basel). 2023 Feb 7;15(4):1063. doi: 10.3390/cancers15041063.
8
Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.循环肿瘤 DNA 对预测接受一线治疗的弥漫性大 B 细胞淋巴瘤患者结局的临床意义。
BMC Med. 2022 Oct 25;20(1):369. doi: 10.1186/s12916-022-02562-3.
9
The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.131I-利妥昔单抗巩固治疗后，应用 18F-FDG PET/CT 评估弥漫大 B 细胞淋巴瘤患者的作用。
PLoS One. 2022 Sep 26;17(9):e0273839. doi: 10.1371/journal.pone.0273839. eCollection 2022.
10
Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma.血浆代谢物预测弥漫性大B细胞淋巴瘤患者的发生及预后
Front Oncol. 2022 Jun 6;12:894891. doi: 10.3389/fonc.2022.894891. eCollection 2022.
本文引用的文献
1
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.随机临床试验入组的弥漫性大 B 细胞淋巴瘤（DLBCL）患者的 24 个月无进展生存（PFS24）和后续结果。
Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.
2
Interim F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma.中期F-FDG PET/CT可提高弥漫性大B细胞淋巴瘤患者S-IPI、R-IPI和NCCN-IPI的预后价值。
Oncol Lett. 2017 Dec;14(6):6715-6723. doi: 10.3892/ol.2017.7093. Epub 2017 Sep 28.
3
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.弥漫性大B细胞淋巴瘤的遗传和功能驱动因素
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.
4
Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?免疫化疗时代弥漫性大B细胞淋巴瘤的预后建模：我们从这里走向何方？
Cancer. 2017 Sep 1;123(17):3222-3225. doi: 10.1002/cncr.30740. Epub 2017 May 2.
5
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.用于霍奇金淋巴瘤和非霍奇金淋巴瘤治疗监测的氟代脱氧葡萄糖正电子发射断层显像（FDG PET）
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110. doi: 10.1007/s00259-017-3690-8. Epub 2017 Apr 14.
6
Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response.弥漫性大B细胞淋巴瘤（DLBCL）分期时的分子特征与氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）代谢体积——反应情况
Clin Cancer Res. 2016 Jul 1;22(13):3414-5. doi: 10.1158/1078-0432.CCR-16-0783.
7
Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?治疗结束时的氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）对治疗前的美国国立综合癌症网络国际预后指数（NCCN-IPI）评分是否具有额外的预后价值？
Br J Haematol. 2017 Apr;177(2):319-320. doi: 10.1111/bjh.14052. Epub 2016 Mar 28.
8
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤患者的分子谱和 FDG-PET/CT 总代谢肿瘤体积改善了诊断时的风险分类。
Clin Cancer Res. 2016 Aug 1;22(15):3801-9. doi: 10.1158/1078-0432.CCR-15-2825. Epub 2016 Mar 2.
9
High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.在利妥昔单抗时代，PET/CT中高总代谢肿瘤体积预示着弥漫性大B细胞淋巴瘤骨髓受累患者的预后更差。
Leuk Res. 2016 Mar;42:1-6. doi: 10.1016/j.leukres.2016.01.010. Epub 2016 Jan 24.
10
Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.F-18 FDG PET/CT量化参数对弥漫性大B细胞淋巴瘤患者无进展生存期的预测价值
Hematology. 2016 Mar;21(2):99-105. doi: 10.1179/1607845415Y.0000000033. Epub 2015 Jul 17.
Zotero 插件